SCIENTIFIC BACKGROUND

CACNA1S, RYR1

Scientific Background

Malignant hyperthermia (MH) is a genetic Ca2+ regulatory disorder of skeletal muscle. In genetically predisposed individuals, the administration of volatile anesthetics (fluranes) and depolarising muscle relaxants (e.g., suxamethasone) can lead to a potentially life-threatening hypermetabolism. The symptoms are very variable and range from moderate forms with low severity to a severe, sudden (fulminant) MH crisis. In the early phase, classic signs of a fulminant MH crisis are tachycardia, hypercapnia, hypoxemia and masseter spasms; in the late phase, acidosis, hyperkalemia, rhabdomyolysis and hyperthermia are added. The antidote dantrolene has reduced the mortality rate in MH crises to <5%. The prevalence of MH in the German population is estimated at 1:10,000. The incidence of a fulminant MH crisis is about 1:60.000. In predisposed patients, the administration of trigger substances must be avoided. Without trigger substances, myopathy is usually inapparent.

 

Pathogenic variants in the ryanodine receptor 1 (RYR1) and the dihydropyridine receptor (voltage-dependent L-type calcium channel, CACNA1S) are associated with a predisposition for MH. Heredity is autosomal dominant with incomplete penetrance. Variants in one of these genes could be identified in about 75% of MH families. The detection of a causative variant enables the identification of other relatives at risk by means of target diagnostics. However, so far only about 50 variants have been categorized as causative by the European Malignant Hyperthermia Group (EMHG). In addition, the studies did not identify variants in the RYR1 or CACNA1S gene in all affected patients, so that a negative molecular genetic finding does not rule out the presence of MH. Therefore, where suspicion exists and there are negative genetic findings or if variants of unclear significance are detected, an in vitro muscle contraction test (IVCT) should be performed to confirm the diagnosis.

 

References

Gonsalves et al. 2019, Clin Pharmacol Ther 105:1338

GENES

CACNA1S, RYR1

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact ...

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more